Dianthus Therapeutics, Inc. (DNTH) stock
DNTHNasdaqPharmaceutical PreparationsFiscal year ends December 31
$86.98−2.57 (-2.87%)
Close on Nov 17, 2026Market cap $4.87BP/E –Yield 0.00%
Dianthus Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Dianthus Therapeutics's operating income for the twelve months ending Sep 30, 2026 was -$236.03M. For fiscal 2025 it was -$177.93M. The highest annual figure on record is -$9.27M in fiscal 2016.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$177.93M | – |
| FY2024 | Dec 31, 2024 | -$101.86M | – |
| FY2023 | Dec 31, 2023 | -$48.17M | – |
| FY2022 | Dec 31, 2022 | -$29.71M | – |
| FY2021 | Dec 31, 2021 | -$74.69M | – |
| FY2020 | Dec 31, 2020 | -$78.70M | – |
| FY2019 | Dec 31, 2019 | -$82.97M | – |
| FY2018 | Dec 31, 2018 | -$59.96M | – |
| FY2017 | Dec 31, 2017 | -$35.73M | – |
| FY2016 | Dec 31, 2016 | -$9.27M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$58.47M | – |
| Q2 FY2026 | Jun 30, 2026 | -$61.48M | – |
| Q1 FY2026 | Mar 31, 2026 | -$46.53M | – |
| Q4 FY2025 | Dec 31, 2025 | -$69.54M | – |
| Q3 FY2025 | Sep 30, 2025 | -$40.29M | – |
| Q2 FY2025 | Jun 30, 2025 | -$34.93M | – |
| Q1 FY2025 | Mar 31, 2025 | -$33.18M | – |
| Q4 FY2024 | Dec 31, 2024 | -$31.92M | – |
| Q3 FY2024 | Sep 30, 2024 | -$29.90M | – |
| Q2 FY2024 | Jun 30, 2024 | -$22.20M | – |
| Q1 FY2024 | Mar 31, 2024 | -$17.84M | – |
| Q4 FY2023 | Dec 31, 2023 | -$12.96M | – |
| Q3 FY2023 | Sep 30, 2023 | -$15.76M | – |
| Q2 FY2023 | Jun 30, 2023 | -$11.78M | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.68M | – |
| Q4 FY2022 | Dec 31, 2022 | -$10.69M | – |
| Q3 FY2022 | Sep 30, 2022 | -$8.25M | – |
| Q2 FY2022 | Jun 30, 2022 | -$18.08M | – |
| Q1 FY2022 | Mar 31, 2022 | -$23.83M | – |
| Q4 FY2021 | Dec 31, 2021 | -$20.14M | – |
| Q3 FY2021 | Sep 30, 2021 | -$18.25M | – |
| Q2 FY2021 | Jun 30, 2021 | -$17.61M | – |
| Q1 FY2021 | Mar 31, 2021 | -$18.70M | – |
| Q4 FY2020 | Dec 31, 2020 | -$19.07M | – |
| Q3 FY2020 | Sep 30, 2020 | -$18.38M | – |
| Q2 FY2020 | Jun 30, 2020 | -$20.01M | – |
| Q1 FY2020 | Mar 31, 2020 | -$21.24M | – |
| Q4 FY2019 | Dec 31, 2019 | -$24.64M | – |
| Q3 FY2019 | Sep 30, 2019 | -$22.64M | – |
| Q2 FY2019 | Jun 30, 2019 | -$19.34M | – |
| Q1 FY2019 | Mar 31, 2019 | -$16.35M | – |
| Q4 FY2018 | Dec 31, 2018 | -$17.93M | – |
| Q3 FY2018 | Sep 30, 2018 | -$16.70M | – |
| Q2 FY2018 | Jun 30, 2018 | -$14.03M | – |
| Q1 FY2018 | Mar 31, 2018 | -$11.31M | – |
| Q4 FY2017 | Dec 31, 2017 | -$8.17M | – |
| Q3 FY2017 | Sep 30, 2017 | -$7.02M | – |
| Q2 FY2017 | Jun 30, 2017 | -$15.73M | – |
| Q1 FY2017 | Mar 31, 2017 | -$4.81M | – |
See a number that looks wrong?